Please check your internet connection and try again.
# Hyoscine butylbromide
## Overview
Hyoscine butylbromide (Scopolamine butylbromide) is a peripherally acting antimuscarinic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier effectively and lacks significant central nervous system effects. It acts as an antispasmodic on the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Gastrointestinal and biliary spasm.
* Irritable Bowel Syndrome (IBS).
* Diagnostic radiology (to reduce motility).
* Palliative care (relief of death rattle/excessive secretions, off-label).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum: 100 mg/day.
* **IV/IM/SC:** 20 mg as a single dose. May repeat after 30 minutes if necessary. Maximum: 100 mg/day.
* **Palliative Care (SC infusion):** 20–60 mg per 24 hours, adjusted based on clinical response.
## Pediatric Dosing
* **Children 6–12 years:** 10 mg orally three times daily.
* **Note:** Not recommended for children <6 years due to lack of safety data/standardized dosing protocols. Consult local pediatric formulary for specific off-label institutional protocols.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Use with caution. No standardized formal dose reduction guidelines exist; clinical judgment is required for patients with severe impairment.
* **Elderly:** Use caution due to increased sensitivity to anticholinergic effects (e.g., urinary retention, constipation).
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon.
* Paralytic ileus or mechanical intestinal obstruction.
* Narrow-angle glaucoma.
* Tachycardia or unstable cardiac conditions.
## Adverse Effects
* **Common:** Dry mouth, dizziness, tachycardia (dose-dependent), visual disturbances (mydriasis/cycloplegia), constipation, urinary retention.
* **Rare:** Anaphylaxis, dyspnea.
## Key Drug Interactions
* **Anticholinergics:** Combined use with TCAs, antihistamines, or antipsychotics increases the risk of side effects like ileus and urinary retention.
* **Dopamine Antagonists:** May result in an antagonistic effect on gastrointestinal motility.
* **Beta-agonists:** May worsen tachycardia.
## Monitoring
* Monitor heart rate, especially with parenteral administration.
* Assess for signs of urinary retention.
* Monitor bowel function (risk of constipation/ileus).
* Monitor ocular symptoms if high doses or frequent administration is required.
## Clinical Pearls
* **Blood-Brain Barrier:** Because it is a quaternary ammonium compound, it does not have the sedative or anti-emetic central effects of hyoscine hydrobromide.
* **Palliative Use:** It is highly effective for reducing "death rattle" in end-of-life care due to its anti-secretory properties.
* **Administration:** When given IV, inject slowly to minimize potential cardiovascular effects.
***
*Disclaimer: This information is for educational purposes and does not substitute for clinical judgment. Dosing protocols can vary by region and institutional policy. Always verify specific dosages and contraindications by consulting current FDA or EMA-approved product labeling or local pharmacy guidelines before prescribing or administering medication.*
